Close menu




 

Fabian Lorenz

  • Small-Caps
  • Micro-Caps

For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

He first came into contact with the stock market and shares during his banking apprenticeship. After completing this in 2000, he gained his first journalistic experience in the editorial department of a financial portal. During his subsequent studies in business administration, he also worked in the area of investor relations.

Since then, he has remained true to the capital markets and is excited to report on every newly discovered interesting story - as well as on long-standing success stories.


Commented by Fabian Lorenz

Commented by Fabian Lorenz on December 7th, 2022 | 10:46 CET

Bayer, BYD, TubeSolar: Stocks for the year-end rally and beyond?

  • Solar
  • photovoltaics
  • Electromobility

Investors are currently positioning themselves for the year-end rally. To that end, today, we look at three exciting and very different stocks. BYD has become Tesla's biggest competitor. But the "honeymoon" for electric vehicles in China is coming to an end, analysts say. What is the story? Bayer has increasingly emerged from the shadow of the glyphosate issue this year. Analysts continue to see upside potential for the DAX company. Just like the new German solar hopeful TubeSolar. If the energy turnaround is to succeed, companies like this are needed. After all, the Augsburg-based company is convincing with its innovative technology and could achieve rapid sales growth in the coming years - does this also apply to the share price?

Read

Commented by Fabian Lorenz on December 1st, 2022 | 11:55 CET

Comeback stocks: Nel, Aurora Cannabis, Barrick Gold, Tocvan Ventures

  • Mining
  • Gold
  • Hydrogen
  • Cannabis

Gold, cannabis and hydrogen could be among the top trends of the coming year - also on the stock market. Due to full order books, Nel could be poised for a comeback in 2023. At least sales are already secured until mid-2024. Now, all that is left is to cut the loss to reach analysts' price targets. Aurora Cannabis has largely completed its turnaround and is also hoping for legalization in Europe and the US. Driven by a strong gold price, mining stocks have already jumped. Now exploration companies should follow. Tocvan Ventures is one of them. And with the gold explorer, investors can look forward to a regular news flow in the coming year. Are the three candidates comeback stocks in 2023?

Read

Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

  • Biotechnology
  • Cancer
  • Investments

Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

Read

Commented by Fabian Lorenz on November 24th, 2022 | 12:40 CET

New year, rising prices? BASF, BioNTech and Manuka Resources - Shares in check

  • Mining
  • Commodities
  • Biotechnology
  • chemicals

As the stock market year 2022 draws to a close, we look ahead to 2023. New year, rising prices? That is what many stock market players are hoping for. The chances are that we will see rising indices again with the end of interest rate hikes in the coming year. Today, we look at three companies likely to attract attention in 2023. At BioNTech, the research pipeline is full to bursting, and there are numerous study results to come. BASF is attractive due to its low valuation and high dividend yield. However, analysts warn of a write-off risk. Manuka Ressources convinces with a profitable core business, and an exciting project in the field of critical raw materials could lead to a revaluation.

Read

Commented by Fabian Lorenz on November 23rd, 2022 | 11:43 CET

China causes a bang in Qatar: Opportunity for Nel ASA, Plug Power, First Hydrogen, ITM Power

  • Hydrogen
  • greenhydrogen

Germany wanted to secure liquefied natural gas (LNG) from Qatar to reduce its dependence on Russia. But now China is digging in and securing LNG supplies from the emirate for the next 27 years. During this time, 108 million tons are to be supplied. Germany only wanted to commit for 5 years. While this does not necessarily take the German government's deal off the table, it does show that gas supplies will continue to be anything but secure or cheap in the future. And it shows how vital hydrogen will be in the future and that policymakers must push for its promotion because hydrogen from renewable energies can at least partially replace natural gas. Companies like Nel ASA, Plug Power and First Hydrogen can benefit from this. In 2022, however, only First Hydrogen was convincing.

Read

Commented by Fabian Lorenz on November 18th, 2022 | 10:15 CET

Shares of Nordex, BYD, and Almonty Industries: Winners of the energy transition

  • Mining
  • Tungsten
  • Electromobility

The energy turnaround is becoming unbearable. But it will take time for the world to switch to renewable energies in private and public life. Today, we take a look at three winning stocks. Among them is BYD. The Chinese carmaker has switched to hybrid and all-electric vehicles and is on track to take Tesla's place as the leading electric carmaker. The first three models for Germany have now been confirmed. At Nordex, sentiment is improving. The share price has jumped, and a large order gives hope. However, wind turbines and batteries cannot be manufactured without raw materials such as tungsten. Now a German research house has taken a closer look at Almonty Industries. The share is on the verge of a revaluation and has a price potential of 100%.

Read

Commented by Fabian Lorenz on November 17th, 2022 | 10:40 CET

Breaking news drives Nel ASA share: What are BioNTech and Kleos Space up to?

  • Space
  • Biotechnology

Growth stocks are currently celebrating a comeback. In particular, when there is also positive news from the company itself, as is the case with Nel ASA. The share of the hydrogen specialist increased by 40% within 4 weeks, and analysts see further potential for their "Top Pick". And then the Norwegians announced a cooperation with General Motors yesterday. BioNTech is also looking good from a chart and operational point of view. The cash box is full, allowing the Mainz-based company to increase production capacities. There is also something happening with space stocks. The valuation of Elon Musk's SpaceX is said to have risen by USD 25 billion in the latest round of financing, which should also improve the environment for Kleos Space. The specialist in space-based high-frequency reconnaissance is facing important weeks.

Read

Commented by Fabian Lorenz on November 10th, 2022 | 12:26 CET

Plug Power after the horror numbers, and what are Varta and Altech Advanced Materials doing?

  • Batteries
  • Electromobility
  • Investments

Climate change, high gas and oil prices and the dependence on "difficult" energy suppliers: There are many reasons why hydrogen and electromobility are among the undisputed topics of the future. Accordingly, shares from these sectors are popular with investors. Plug Power is one of the favorites. The Americans have disappointed (again) with their latest quarterly figures, but the share price is still rising, and analysts are also positive. Battery specialist Altech Advanced Materials is also currently doing well. The cooperation with Fraunhofer in the field of solid-state batteries is taking shape. Varta, on the other hand, is currently working on bottoming out, but analysts advise selling.

Read

Commented by Fabian Lorenz on November 9th, 2022 | 13:31 CET

BioNTech, Porsche and Pathfinder Ventures - Looking good

  • Camping
  • RV
  • Biotechnology

BioNTech's figures were convincing, and the chart looks good again. Porsche is doing well. Not all analysts see further price potential and the price targets diverge. However, a promotion to the DAX beckons. Pathfinder Ventures is also benefiting from surprisingly high demand. The winter camping resort offers are practically sold out. But first to BioNTech. After competitor Moderna had disappointed last week, the quarterly figures of the Mainz-based biotech Company were convincing. And due to the full pipeline, investors can expect a lively news flow in the coming year. Analysts are bullish.

Read

Commented by Fabian Lorenz on November 3rd, 2022 | 12:01 CET

BioNTech, Moderna and Defence Therapeutics right in the middle of the billion-dollar mRNA market! And Bayer?

  • Biotechnology
  • vaccine
  • Cancer

BioNTech and Moderna's mRNA-based vaccines have successfully contributed to the containment of the COVID-19 pandemic. This has helped the relatively new technology for developing vaccines and other drugs to make a breakthrough. According to Precedence Research market researchers, the mRNA therapeutics market is expected to exceed USD 128 billion by 2030. The average annual growth would be around 13%. German top dog BioNTech is betting heavily on vaccines to fight cancer, among other things. Defence Therapeutics is now also entering the billion-dollar market, continuing the positive newsflow of recent weeks. The Canadians are opening up their platform for mRNA research, and their valuation is anything but expensive. Bayer is also too cheap at the moment. Analysts at least see a good 50% price potential.

Read